Asthma – Current Treatment – Detailed, Expanded Analysis (EU5)

The asthma market in the EU5 is highly competitive. Many approved agents are available, including maintenance therapies—LABA/ICS FDCs (e.g., GSK’s Seretide and Relvar, AstraZeneca’s Symbicort, branded generics and generics), ICSs (e.g., AstraZeneca’s Pulmicort, Teva’s Qvar), leukotriene inhibitors, biologics (e.g., Novartis’s Xolair, GSK’s Nucala, AstraZeneca’s Fasenra), and a LAMA (Boehringer Ingelheim’s Spiriva, generics)—and rescue therapies, such as SABAs (e.g., GSK’s Ventolin, Teva’s ProAir). Understanding patient pathways and drivers of treatment decisions for key players in asthma can help optimize these agents’ uptake and provide valuable insights for developers of novel brands entering the market.

QUESTIONS ANSWERED

· What patient share do key drug classes and individual therapies garner in intermittent, mild, moderate, and/or severe asthma?

· Which main factors influence treatment practices in asthma? What is the sequencing of treatment for asthma? What do physicians report as recent and anticipated changes in their treatment practices?

· What are the main reasons why certain eligible patients do not receive asthma biologics? What features drive the choice of a biologic in asthmatics?

· Which features drive the choice of a LABA/ICS FDC agent? What are the main obstacles to prescribing individual branded and generic LABA/ICS FDCs?

· What are the compliance and persistency rates for key products on the market?

PRODUCT DESCRIPTION

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Geographies 

EU5 (Germany, France, Spain, Italy, United Kingdom).

Primary Research

Survey of 250 European pulmonologists.

Key Drugs Covered

Seretide, Symbicort, Relvar, Formodual / Foster, Flutiform, Spiriva, Xolair, Nucala, Cinqaero, Fasenra, Dupixent, montelukast.

Key Insights

  • Factors influencing disease management and treatment decisions.
  • Drivers and constraints of treatment selection.
  • Physician-reported treatment practices and brand-level patient shares.
  • Rationale for changes in treatment approach.
  • Physician insight on persistency and compliance.
  • Physician-reported recent/anticipated changes in brand usage or treatment approach.

Table of contents

  • Asthma - Current Treatment - Detailed, Expanded Analysis (EU5)
    • Current Treatment: Physician Insights - Asthma EU5 -October 2020